🔴 Telix Pharmaceuticals is trading 10.13% down today

Telix Pharmaceuticals is trading at A$15.62, down -10.13%, with no specific August 24 catalyst confirmed.

• The August 24, 2026 decline follows Telix’s August 20 half-year results, which reported US$477 million revenue.
• The company reaffirmed FY2026 guidance of US$950–970 million and announced an ATM facility; no sales were reported.
• Earlier coverage cited broader biotech weakness, but no source confirms a specific August 24 catalyst.